Stocktoria
Rallybio Corp RLYB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-07-29
Rallybio Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -3853.6% | -9511.9% | — | — | — |
| Net margin | -1046.4% | -9084.1% | — | — | — |
| FCF margin | — | -7748.7% | — | — | — |
| Return on assets | -14.4% | -84.8% | -64.5% | -36.9% | -25.8% |
| Return on equity | -15.5% | -93.7% | -70.2% | -39.4% | -26.8% |
| Current ratio | 14.50 | 10.87 | 12.39 | 16.71 | 27.61 |
| Revenue growth | 34.9% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001739410 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.